Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical problem of chronic hand eczema.

The British journal of dermatology·2026
Same author

Topical Salbutamol Cutaneous Gel Is Safe in a Double-Blind, Placebo-Controlled, Randomized Trial of Scarring from Sutured Wound Margins on the Arms of Healthy Human Volunteers.

JID innovations : skin science from molecules to population health·2026
Same author

Comment on: 'Epimax-Related Ocular Surface Toxicity (EROST): the Glasgow experience'.

Eye (London, England)·2025
Same author

The UK-Irish Atopic eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort.

The British journal of dermatology·2025
Same author

An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.

The British journal of dermatology·2024
Same author

Sensitisation to the acrylate co-polymers glyceryl acrylate/acrylic acid co-polymer, sodium polyacrylate and acrylates/C10-30 alkyl acrylate cross-polymer (Carbopol®) is rare.

Contact dermatitis·2024
Same journal

Letter to the editor in reply to "Ethics of Rising Trends in Dermatology Publications Using Large-Scale Databases".

Clinics in dermatology·2026
Same journal

Ethics of suggesting image-guided superficial radiation therapy on the pathology report.

Clinics in dermatology·2026
Same journal

Tanorexia: The Psychodermatology of Compulsive Tanning.

Clinics in dermatology·2026
Same journal

Ear manifestations of connective tissue diseases: A dermatologic, histopathologic, and clinicopathologic review.

Clinics in dermatology·2026
Same journal

Discovery of an intravenous drug injection site: A meticulous cutaneous examination provides the forensic dermatologic clue to a diagnosis of homicide.

Clinics in dermatology·2026
Same journal

Sherlock Holmes and the mystery of the deadly diet.

Clinics in dermatology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Extraction of Tissue Antigens for Functional Assays
08:32

Extraction of Tissue Antigens for Functional Assays

Published on: September 10, 2012

Insulin allergy.

Mohammad K Ghazavi1, Graham A Johnston

  • 1Department of Dermatology, Leicester Royal infirmary, University Hospitals of Leicester, Infirmary Square, Leicester LE1 5WW, UK. mohammad.ghazavi@uhl-tr.nhs.uk

Clinics in Dermatology
|April 19, 2011
PubMed
Summary
This summary is machine-generated.

Insulin reactions are rare but clinically significant, with modern recombinant human insulin greatly reducing allergy risks. Preservatives, not just insulin, can cause these adverse events.

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Experiment Videos

Last Updated: Jun 2, 2026

Extraction of Tissue Antigens for Functional Assays
08:32

Extraction of Tissue Antigens for Functional Assays

Published on: September 10, 2012

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Area of Science:

  • Endocrinology
  • Immunology
  • Dermatology

Background:

  • Insulin therapy has evolved from crude animal extracts to highly purified and recombinant human forms.
  • Adverse reactions to insulin, though rare, pose significant clinical challenges.
  • Historically, bovine and porcine insulins were associated with higher allergenicity than current preparations.

Purpose of the Study:

  • To review the incidence, types, and causes of insulin-induced allergic reactions.
  • To discuss the diagnostic approaches for identifying insulin hypersensitivity.
  • To highlight the impact of insulin purification and recombinant technology on reducing adverse events.

Main Methods:

  • Review of historical and current literature on insulin allergy.
  • Analysis of reported cases of adverse reactions to insulin products.
  • Description of immunological mechanisms underlying different reaction types.
  • Summary of diagnostic methods including skin testing and biopsy.

Main Results:

  • The prevalence of allergic reactions to insulin products is approximately 2%, with fewer than one-third linked to the insulin molecule itself.
  • Recombinant human insulin has significantly decreased the incidence of allergic reactions compared to older insulin preparations.
  • Preservatives like zinc, protamine, and meta-cresol are common causes of non-insulin-related reactions.
  • Allergic reactions manifest as Type I (immediate), Type III (Arthus), and Type IV (delayed hypersensitivity).

Conclusions:

  • Modern insulin formulations have drastically reduced allergic reactions.
  • Distinguishing between insulin-related and preservative-related allergies is crucial for management.
  • A range of diagnostic tests are available to investigate suspected insulin hypersensitivity.